MovDisordV3, Main, Exploration, bibRecord, 005956

A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

Identifieur interne : 005956 ( Main/Exploration ); précédent : 005955; suivant : 005957

A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

Auteurs : Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France]

Source :

Movement Disorders [ 0885-3185 ] ; 1995-09.

RBID : ISTEX:806E4F3F8D16EBA065D77708F85BE5849D8DD7A8

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Bromocriptine, Bromocriptine (therapeutic use), Dopamine Agonists (therapeutic use), Dopamine agonists, Drug Therapy, Combination, Dyskinesia, Drug-Induced (etiology), Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Middle Aged, Parkinson Disease (drug therapy), Pergolide, Pergolide (therapeutic use).
MESH :
- chemical , adverse effects : Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Dopamine Agonists, Levodopa, Pergolide.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- Aged, Drug Therapy, Combination, Humans, Middle Aged.

Abstract

The efficacy of pergolide as adjunct to levodopa therapy was compared to that of bromocriptine in 12 parkinsonian patients with fluctuating motor disability and levodopa‐induced dyskinesias (mean age of onset, 50.6 ± 8 years; Hoehn and Yahr stage between II and IV; mean basal UPDRS motor score, 30.6 ± 8.6), in a double‐blind crossover study. After an 8‐day habituation to each agonist, an acute challenge of a supraliminal dose of levodopa (“levodopa test”) was performed in association with either 1 mg pergolide or 10 mg bromocriptine. The delay to onset and the duration of therapeutic benefit, the percentage improvement in motor disability, and the severity of onset and peak‐dose dyskinesias were evaluated. Both agonists significantly increased the duration of therapeutic benefit, but pergolide more so than bromocriptine (p = 0.02). Pergolide also tended to reduce the severity of dyskinesias and wes globally perceived by the patients to be more efficacious than bromocriptine on parkinsonian symptoms and fluctuations. This study illustrated the usefulness of the “levodopa test” in evaluating, objectively, the effects of dopamine agonists.

Url:

https://api.istex.fr/document/806E4F3F8D16EBA065D77708F85BE5849D8DD7A8/fulltext/pdf

DOI: 10.1002/mds.870100522

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine</title>
<author><name sortKey="Bonnet" sort="Bonnet" uniqKey="Bonnet" last="Bonnet">Bonnet</name>
</author>
<author><name sortKey="Serre, I" sort="Serre, I" uniqKey="Serre I" first="I." last="Serre">I. Serre</name>
</author>
<author><name sortKey="Marconi, R" sort="Marconi, R" uniqKey="Marconi R" first="R." last="Marconi">R. Marconi</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:806E4F3F8D16EBA065D77708F85BE5849D8DD7A8</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1002/mds.870100522</idno>
<idno type="url">https://api.istex.fr/document/806E4F3F8D16EBA065D77708F85BE5849D8DD7A8/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002D65</idno>
<idno type="wicri:Area/Istex/Curation">002D65</idno>
<idno type="wicri:Area/Istex/Checkpoint">003D87</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Bonnet:a:combined:levodopa</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8552122</idno>
<idno type="wicri:Area/PubMed/Corpus">004923</idno>
<idno type="wicri:Area/PubMed/Curation">004923</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004A36</idno>
<idno type="wicri:Area/Ncbi/Merge">004A60</idno>
<idno type="wicri:Area/Ncbi/Curation">004A60</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A60</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Bonnet A:a:quot:combined</idno>
<idno type="wicri:Area/Main/Merge">008B18</idno>
<idno type="wicri:Area/Main/Curation">005956</idno>
<idno type="wicri:Area/Main/Exploration">005956</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine</title>
<author><name sortKey="Bonnet" sort="Bonnet" uniqKey="Bonnet" last="Bonnet">Bonnet</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie and INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Serre, I" sort="Serre, I" uniqKey="Serre I" first="I." last="Serre">I. Serre</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinique des Maladies du Système nerveux, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marconi, R" sort="Marconi, R" uniqKey="Marconi R" first="R." last="Marconi">R. Marconi</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie and INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie and INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
</placeName>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Fédération de Neurologie and INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1995-09">1995-09</date>
<biblScope unit="vol">10</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="668">668</biblScope>
<biblScope unit="page" to="671">671</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">806E4F3F8D16EBA065D77708F85BE5849D8DD7A8</idno>
<idno type="DOI">10.1002/mds.870100522</idno>
<idno type="ArticleID">MDS870100522</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Bromocriptine</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dopamine agonists</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Pergolide</term>
<term>Pergolide (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Bromocriptine</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
<term>Pergolide</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Middle Aged</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The efficacy of pergolide as adjunct to levodopa therapy was compared to that of bromocriptine in 12 parkinsonian patients with fluctuating motor disability and levodopa‐induced dyskinesias (mean age of onset, 50.6 ± 8 years; Hoehn and Yahr stage between II and IV; mean basal UPDRS motor score, 30.6 ± 8.6), in a double‐blind crossover study. After an 8‐day habituation to each agonist, an acute challenge of a supraliminal dose of levodopa (“levodopa test”) was performed in association with either 1 mg pergolide or 10 mg bromocriptine. The delay to onset and the duration of therapeutic benefit, the percentage improvement in motor disability, and the severity of onset and peak‐dose dyskinesias were evaluated. Both agonists significantly increased the duration of therapeutic benefit, but pergolide more so than bromocriptine (p = 0.02). Pergolide also tended to reduce the severity of dyskinesias and wes globally perceived by the patients to be more efficacious than bromocriptine on parkinsonian symptoms and fluctuations. This study illustrated the usefulness of the “levodopa test” in evaluating, objectively, the effects of dopamine agonists.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
<orgName><li>Hôpital de la Salpêtrière</li>
</orgName>
</list>
<tree><country name="France"><noRegion><name sortKey="Bonnet" sort="Bonnet" uniqKey="Bonnet" last="Bonnet">Bonnet</name>
</noRegion>
<name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<name sortKey="Marconi, R" sort="Marconi, R" uniqKey="Marconi R" first="R." last="Marconi">R. Marconi</name>
<name sortKey="Serre, I" sort="Serre, I" uniqKey="Serre I" first="I." last="Serre">I. Serre</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005956 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005956 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:806E4F3F8D16EBA065D77708F85BE5849D8DD7A8
   |texte=   A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.